Vygon’s Vadsite and Bionector Meet the MHRA Standards for Safer IV Therapy

Vygon has confirmed that its needle-free connectors, Vadsite and Bionector, are fully aligned with the latest recommendations from the Medicines and Healthcare products Regulatory Agency (MHRA), reinforcing its commitment to patient safety and infection prevention in intravenous (IV) therapy.

The MHRA’s updated recommendations focus on enhancing infection prevention and ensuring compatibility across IV therapy systems.

Vadsite, Vygon’s negative displacement reliable needle-free connector, is fully compatible with the updated MHRA guidance, offering healthcare professionals a trusted solution for safe and effective IV access.

Bionector, the neutral needle-free connector in Vygon’s IV therapy portfolio, also meets the MHRA’s recommendations, when used with an appropriate adaptor.

By confirming its needle-free connectors meet the latest MHRA standards, Vygon continues to play a vital role in reducing the risk of bloodstream infections and improving patient outcomes.

Healthcare professionals can be confident that Vadsite and Bionector offer not only ease of use and reliability but also the assurance of regulatory compatibility, helping to maintain the highest standards of care across NHS and private healthcare settings.